| Name | GSK-3 inhibitor 4 |
| Description | GSK-3 inhibitor 4 is an orally active and brain-permeable compound that acts as a triple inhibitor of GSK-3, CDK2, and CDK5, with IC50 values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM (CDK2), and 0.68 μM (CDK5). It effectively reduces Tau protein levels and can be used in the study of Alzheimer's disease. |
| In vitro | GSK-3 inhibitor 4 (compound 40) demonstrates excellent selectivity and efficacy against CDK2 (840-fold, IC50 = 0.47 μM), CDK5 (1200-fold, IC50 = 0.68 μM), GSK-3β (IC50 = 0.56 nM), and GSK-3α (IC50 = 0.45 nM). It also exhibits good permeability and a high capacity for binding to plasma proteins and brain tissue due to its lipophilicity.[1] |
| In vivo | GSK-3 inhibitor 4 (10 mg/kg; p.o.) reduced pTau396 by 37% when administered orally as a nanosuspension. GSK-3 inhibitor 4 (2 mg/kg, i.v.; 10 mg/kg, p.o.) exhibits low to moderate clearance (15.8 to 23.3 mL/min/kg) and is well absorbed orally in solution.[1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (123.95 mM), Sonication is recommended.
|
| Keywords | GSK3inhibitor4 | GSK-3 inhibitor 4 | GSK-3 | GSK3 | CDK5 | CDK2 |
| Inhibitors Related | Ribociclib | Amantadine | 2-Chloropyrazine | Kojic acid | Cromolyn sodium | Abemaciclib | 4-Chloro-2'-bromoacetophenone | Ethyl linoleate | 2,4,6-Trihydroxybenzoic acid | Palbociclib | (E/Z)-10-Hydroxy-2-decenoic acid | Sodium Oxamate |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Autophagy Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library |
United States
